69results about How to "Slow drug release" patented technology

The invention is directed to a drug delivery device for controlled release of a drug, such as methylphenidate hydrochloride. The drug deliver device has a drug core, having a plug embedded therein, and at least a first coating that at least partially surrounds the core. The plug may be hollow or solid, and swells upon absorption of water, bursting through the first coating. The drag delivery device enables zero-order drug release profiles as well as more complicated release profiles to be obtained.

The invention relates to an application of a long effective curcumin derivative in preparing an anti-tumor disease drug. The long effective curcumin derivative is an ester which is formed in such a way that C1 to C50 saturated or unsaturated fatty acids or acyls thereof react with hydroxyl groups of curcumin substances by esterification respectively and independently. Through the research on the anti-tumor action of various animal models, the long effective curcumin derivative can reserve the inherent anti-tumor drug effect of the curcumin and also has the effects of the slow release and the prolongation of the drug effect and a favorable prospect of clinical application. The long effective curcumin derivative can be also used for preparing anti-tumor drinks, foods, food additives or health products.

A miniaturized pre-filled, single-use, disposable, small volume medication nebulizer unit for medicinal use that delivers a mist of properly sized aerosol particles of medicament to the patient with a very high level of efficiency. The nebulizer can be effectively used in conjunction with conventional tee and mouthpiece patient interface devices as well as with more sophisticated interface devices such as dosimetric/reservoir systems, or mechanical ventilator systems.

The invention relates to a liposome nano carrier in-situ gelling preparation for eyes containing epidermal growth factor, which is prepared from epidermal growth factor, lipid material, emulsifying agent, thickening agent, isotonic conditioning agent, bacteria inhibitor, pH regulator and purified water, wherein non-irritating phosphatide is employed as the emulsifying agent, macromolecular material having ion and/or pH responsive characteristics is used as the thickening agent.

The invention provides a paclobutrazol micro-capsule suspension preparation provided with sustained-release function, which includes the following components according to 100 parts by weight: 10 to 30 parts of film-forming materials, 5 to 40 parts of paclobutrazol, 5 to 10 parts of emulsifying agent and the rest parts of water. The potency of the suspension preparation is more moderate, the potency releases slower and lasts long, thus ensuring the adjustment of steady growth of plants and having the sustained-release function. The invention also provides a preparation method of the paclobutrazol micro-capsule suspension preparation.

Described are computer-implemented methods and apparatuses, including computer program products, for estimating an optimal value for each input factor of a design space. The design space is defined by the input factors and output responses for a physical process. The optimal values for the input factors represent a starting point for estimating the design space. Data is received for the input factors, the output responses and criteria. An initial design space is estimated based on the received data. The optimal values for the input factors are determined from the initial design space.

Specific drug delivery to tumor cells without affecting normal cells is a major challenge in cancer treatment. The present invention incorporates embedding nonionic surfactant vesicles (niosomes) containing an anti-cancer therapeutic agent with chlorotoxin into a thermosensitive chitosan hydrogel network. Chitosan has mucoadhesive property which can be used in the targeting of the tumor cells with the mucin over expression. Chlorotoxin is a 36 amino acid peptide obtained from Leiurus quinquestriatus scorpion venom which binds preferentially to tumor cells of neuroectodermal origin but not to normal cells. The incorporation of chlorotoxin along with niosomes in the chitosan hydrogel is used as the second targeting strategy to further improve the specific delivery of drugs to tumor cells such as glioma.

The invention relates to a vinflunine liposome preparation and the preparation method thereof. The vinflunine liposome preparation mainly comprises vinflunine or salt, phospholipid, cholesterin and polyethylene glycol-distearoyl phosphatidyl ethanolamine of the vinflunine, wherein salt, phospholipid, cholesterin and polyethylene glycol-distearoyl phosphatidyl ethanolamine are pharmaceutically acceptable, and the vinflunine liposome preparation can be prepared into an injection or a lyophilized preparation. The preparation method is simple in technology, easy to operate and suitable for industrial production, and long-circulating vinflunine liposomes prepared by using the method are high in encapsulation rate and good in stability.

The invention discloses compound intrauterine infusion liquid of western medicine and Chinese traditional medicine for treating cow endometritis and a preparation method thereof, the infusion liquid takes oxytetracycline, motherwort herb, peach seed, Chinese angelica, Szechuan lovage rhizome, membranous milkvetch root, liquoric root and a plurality of excipients as raw materials and is prepared by decoction, filtration, concentration, pumping filtration, concentration, spray drying, micro-powderization of oxytetracycline, homogenization and other processes; the infusion liquid has the advantages that firstly, the raw materials constitute the safe, effective and comprehensive infusion liquid which can not only realize the rapid anti-inflammation, but can also restore the functions of the body with the diseases after the inflammation, promote the pregnancy and treat the infertility; secondly, the infusion liquid adopts the formulation of microparticle suspension, the unit solvent drug-loaded amount is great, the drug delivery volume is small, the chemical properties of the drug microparticles are stable, the bioadhesion is stronger, the drug release is sustained, the infusion liquid can be adhered on the cow uterine endometrium for a long time, thus directly stimulating a uterine receptor, ensuring the drug to be fully absorbed as well as better and rapidly playing the roles.

Disclosed is a Chinese medicinal gelling agent which comprises, 7.5-12.5 wt% of mentha-camphor, 5.5-8.5 wt% of curcuma longa pieces, 5.5-8.5 wt% of dahurian angelica root pieces, 2.5-4.4 wt% of pollen pieces, 2.5-4.4 wt% of red peony root pieces, 2-4 wt% of nitrogen ketone, 1.5-3 wt% of Carbomer, 0.3-0.5 wt% of polysorbate, 0.1-0.3 wt% of triethanolamine and balancing water. The invention also discloses the preparing process.

The invention discloses a traditional Chinese medicine microecological preparation and a preparation method thereof. The traditional Chinese medicine microecological preparation is prepared by adopting traditional Chinese medicine ultra-fine powder as the main ingredient of fermentation culture media, adopting bacillus coagulans as the producing strain and adopting the fermentation technology. The traditional Chinese medicine ultra-fine powder comprises the composition of 20-60 parts of milkvetch roots, 20-40 parts of glossy privet fruits and 20-40 parts of epimedium herb with the grain size of 1-60 micrometers. The preparation method comprises the steps of strain separation and purification, inclined face activation, seed solution preparation, fermentation and culture, ingredient extraction, granulation forming and the like. The traditional Chinese medicine microecological preparation and the preparation method thereof have the advantages that the medicine effect is good, the extraction rate is high, and the medicinal material utilization rate is high.

The invention relates to the field of medicines, and particularly relates to a liraglutide multivesicular liposome and a preparation method and an application thereof. The liraglutide multivesicular liposome provided by the invention comprises liraglutide, a membrane material, an osmotic pressure regulator and a stabilizer. The liraglutide multivesicular liposome prepared by the invention has goodstability, high drug encapsulation rate, large drug loading capacity, slow and steady drug release rate and no burst release phenomenon, significantly improves the bioavailability of the drug, thereby improving the curative effect, reduces dose-related side effects of the drug and medication cost and has a higher application value. Experiments shows that the liposome provided by the present invention can continuously release the drug in vitro for about 432 hours, and provide a stable blood concentration in vivo, significantly prolongs in-vivo retention time compared to other injections, showsobvious pharmacokinetic characteristics of a sustained release preparation, can provide a normal steady blood glucose level, plays hypoglycemic effect for 312 hours, and has the relative bioavailability of 661% to injections.

The invention discloses a preparation method of a paliperidone sustained release microsphere injection. The preparation technology comprises the following steps: (1) paliperidone and an acid anhydrides reagent are respectively dissolved in a solvent to be subjected to esterification reaction under the effect of an alkaline catalyst; (2) the esterification product obtained in the step (1) is dissolved in anhydrous dichloromethane to be subjected to acylation reaction with the added acylation reagent with DMF (N, N- dimethylformamide) being the catalyst; (3) the acylated paliperidone is subjected to esterification reaction with polylactic acid (PLA) through chemical bond bonding; (4) paliperidone sustained release microspheres are prepared by adopting solvent evaporation method, and the paliperidone sustained release microspheres are prepared into the microsphere injection after being cooled and dried. The preparation method is safe to operate, mild in reaction condition and simple and clear in steps; the total yield reaches 50% or above; the particle sizes of the obtained paliperidone microspheres are 30-50 micron; the paliperidone sustained release microsphere injection provided by the invention is high in drug loading capacity, stable in drug release, long in drug release time and good in sustained release effect.

The invention relates to new application of biguanide drugs, in particular to application of biguanide drugs in preparation of drugs for preventing or weakening pulmonary fibrosis. The pulmonary fibrosis is complications produced by EGFR-TKI or ALK-TKI in treatment of non-small cell lung cancers. The biguanide drugs can avoid the complications produced by the EGFR-TKI or ALK-TKI in treatment of non-small cell lung cancers, effectively improve an EGFR-TKI or ALK-TKI treatment effect and reduce occurrence and development of patients' complications.

The invention relates to an application of a long effective curcumin derivative in preparing an anti-depression drug. The long effective curcumin derivative is an ester which is formed in such a way that C1 to C50 saturated or unsaturated fatty acids or acyls thereof react with hydroxyl groups of curcumin substances by esterification respectively and independently. Through the research on the anti-depression action of various animal models, the long effective curcumin derivative can reserve the inherent anti-depression drug effect of the curcumin and also has the effects of the slow release and the prolongation of the drug effect and a favorable prospect of clinical application. The long effective curcumin derivative can be also used for preparing anti-depression drinks, foods, food addiitives or health products.

The subject provides a sustained release tablet comprising the following components: a) a uniform admixture of an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure: wherein R1, R2, and R3 are independently the same or different and are hydrogen, a C1-C6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3; and a binder, and b) a hydroxypropylmethyl cellulose, a process for manufacturing the tablet and a method of treating neuropathic pain, epilepsy, mania in bipolar disorder, a headache disorder, pain or of effecting pain prophylaxis in a subject.

The invention discloses a compound botanical fungiticide, which comprises the following raw materials by mass percentage: 5%-30% of natural capsaicin, 5%-25% of ageratina adenophora extract, 1%-15% ofphytolacca acinosa extract, 1%-10% of gynostemma pentaphyllum extract, 2.5%-15% of an emulsifier, 3%-10%of a surfactant, 1%-5% of a synergist, 0.5%-5% of an antioxidant, and the balance deionized water. The invention has the beneficial effects that: the compound botanical fungiticide provided by the invention can be applied to control of common diseases in fruits, vegetables, flowers and the like, and the specific diseases to be controlled include: anthracnose, brown patch, black spot and the like in mangos, pears and apples; anthracnose, black spot, botrytis cinereal and the like in Chinesecabbage, tomatoes, cucumber and the like; root rot, late blight, anthracnose and the like in panax notoginseng, chili and tobacco.